How We Got Here
In 2023, a month of Wegovy cost over $1,300 at list price. Insurance coverage was spotty. Compounding pharmacies were just starting to fill the gap. Fast forward to mid-2026: Novo Nordisk's self-pay Wegovy is ~$349/month. Compounded semaglutide runs $99–299. Medicare offers $50. The market is unrecognizable from three years ago.
What drove the change: compounding competition forced brand-name pricing down; oral pills are cheaper to manufacture than biologics; Medicare coverage added massive buyer leverage; and Eli Lilly and Novo Nordisk are in a direct war for market share.
The Current Price Landscape
| Channel | Monthly Cost | Who It's For |
|---|---|---|
| Medicare Bridge | $50 | Part D beneficiaries, BMI ≥30 or ≥27 with comorbidity |
| Compounded (telehealth) | $99–299 | Self-pay patients, no insurance requirement |
| Brand self-pay (Wegovy/Zepbound) | $349–399 | Patients wanting FDA-approved products |
| With commercial insurance | $0–150 copay | Patients with favorable coverage |
| TrumpRx.gov programs | Varies | Patients qualifying for manufacturer assistance |
The Pill Effect on Pricing
Oral Wegovy launched January 2026. Orforglipron (Foundayo) is expected by late June. Pills are cheaper to manufacture than biologic injectables, and competition between the two should put downward pressure on pricing. When orforglipron launches, Novo Nordisk will face a direct competitor that patients can take more conveniently — creating incentive to compete on price.
The Compounding Question
The FDA's April 30 proposal to remove GLP-1s from the 503B Bulks List could reduce competition from large-scale compounders — which has been the primary force driving brand-name prices down. If 503B compounding is eliminated, brand manufacturers lose their biggest pricing pressure. Patient-specific 503A compounding continues, but at smaller scale.
Watch this space: the June 29 comment deadline could influence whether compounding competition survives in its current form.
Embody
Injectable semaglutide with flat-rate pricing, custom metabolic reports, and HSA/FSA acceptance. No dose-escalation pricing games.
Compare Now →The Insurance Reality
Despite lower brand-name prices, insurance coverage for weight loss is getting more restrictive in some markets. Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity entirely. Others have raised BMI thresholds or added step therapy requirements. The irony: prices are coming down while coverage is tightening.
This makes telehealth providers with direct-pay compounded options particularly relevant for patients who are insured but not covered for weight loss.
Strut Health
Strut offers GLP-1 programs designed for men, with physician oversight and straightforward pricing.
Compare Now →Our Take
Summer 2026 is the best time in history to start GLP-1 treatment from a cost perspective. The question isn't whether you can afford it — it's which pathway offers the best value for your situation. Medicare beneficiaries should explore the Bridge. Self-pay patients should compare flat-rate compounded providers against brand self-pay pricing. And everyone should be aware that the FDA's 503B proposal could change the competitive landscape within months.